Sign In
Buy VNRX
$1.21
-0.130 (-9.70%)
At Close: Jun 23, 2026
VolitionRx Announces Collaboration with Sysmex
08:15am, Wednesday, 17'th Jun 2026
HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader
VolitionRx Announces Pricing of $4.6 Million Public Offering
06:30pm, Sunday, 07'th Jun 2026
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NY
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
08:12am, Wednesday, 03'rd Jun 2026
Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
08:17am, Wednesday, 27'th May 2026
Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., May 27, 202
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
03:30pm, Friday, 15'th May 2026
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
04:10pm, Thursday, 14'th May 2026
Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
08:19am, Monday, 11'th May 2026
Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
08:17am, Wednesday, 06'th May 2026
The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
08:17am, Wednesday, 29'th Apr 2026
HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the succes
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
08:12am, Thursday, 23'rd Apr 2026
HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, th
Volition Launches rNuQ™ Webshop Broadening Product Range
07:30am, Monday, 20'th Apr 2026
HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range
VolitionRX Q4 Earnings Call Highlights
01:07am, Friday, 03'rd Apr 2026
VolitionRX (NYSEAMERICAN:VNRX) outlined what management described as a "transformational" period during its full fiscal year 2025 earnings call, highlighting early steps toward routine clinical use of
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
01:42pm, Wednesday, 01'st Apr 2026
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
04:05pm, Tuesday, 31'st Mar 2026
Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
08:16am, Tuesday, 31'st Mar 2026
HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2
